Management and Long-Term Outcomes of Persistent Tachypnea of Infancy/Neuroendocrine Cell Hyperplasia of Infancy: A European Multicenter Retrospective Study - PubMed
7 days ago
- #Pediatric Pulmonology
- #Clinical Management
- #Interstitial Lung Disease
- Persistent tachypnea of infancy (PTI), also known as neuroendocrine cell hyperplasia of infancy (NEHI), is a common childhood interstitial lung disease.
- The study involved 378 children from 73 centers across 17 European countries, with a median age at diagnosis of 9 months.
- Treatment strategies varied widely, including oxygen supplementation (75.9%), inhaled bronchodilators/glucocorticoids (62.4%), systemic glucocorticoids (37.0%), and nutritional support (33.8%).
- 53.6% of children on oxygen therapy were weaned off by a median age of 24 months.
- Long-term follow-up data showed improvement in symptoms by age 4, but some patients had persistent issues like hypoxemia and abnormal pulmonary function into adolescence.
- The study highlights the need for standardized, evidence-based guidelines due to significant variability in treatment practices across Europe.